Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers

25. juni 2018 opdateret af: Yungjin Pharm. Co., Ltd.

A Dose Double-blind,Placebo-controlled,Single Dosing,Dose-escalation Clinical Trial to Investigate the Safety,Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects

The purpose of this study is to investigate the safety and tolerability of MB12066 after a single oral dose and to investigate the pharmacokinetic characteristics of MB12066 after a single oral dose.

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Detaljeret beskrivelse

  • Safety/ Tolerability evaluation

    -Adverse events, Physical examinations, Vital signs, ECG (including continuous ECG monitoring), Laboratory tests (including hematology, chemistry, coagulation, PBS, NAD(P)+/NAD(P)H ratio, urinalysis), CIC

  • Pharmacokinetic Evaluation

    • Serial blood samples and urine collections for pharmacokinetic evaluations will be conducted between 0 (pre-dose) and 96 hours after a single oral dose.
    • Blood sampling time pre-dose, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h post-dose
    • Urine collection time 0h - 6h, 6h - 12h, 12h - 24h, 24h - 48h, 48h - 72h
    • Evaluation parameters AUClast, AUCinf, Cmax, Tmax, t1/2, Vd/F, CL/F, Ae, fe, CLR

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

50

Fase

  • Fase 1

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

20 år til 45 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Han

Beskrivelse

Inclusion Criteria:

  1. Subject is informed of the investigational nature of this study and voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB) - approved informed consent prior to performing any of the screening procedures
  2. Healthy Korean male volunteers, age ranged 20 to 45 years (both inclusive)
  3. A subject with body weight between 60 kg (inclusive) and 90 kg (exclusive) and body mass index (BMI) between 18.5 (inclusive) and 25 (exclusive). ☞ BMI (kg/m2) = weight (kg) / {height (m)}2
  4. Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the laboratory reference ranges for the relevant laboratory tests (unless the investigator considers the deviation to be irrelevant for the purpose of the study)

Exclusion Criteria:

  1. A subject with history of allergies including drug allergies (aspirin, antibiotics, etc.), or history of clinically significant allergies
  2. A subject with clinical evidence or history of hepatic (including carrier of hepatitis virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic, oncologic, psychiatric, or cardiovascular disease
  3. A subject with history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug
  4. A subject whose hemoglobin(Hb) level < 12 g/dL
  5. A subject with fasting plasma glucose (FPG) level ≤ 70 mg/dL or ≥ 126 mg/dL
  6. A subject with HbA1c level ≥ 7.0 mmol/L
  7. A subject whose systolic blood pressure (SBP) ≤ 90 mmHg or ≥ 140 mmHg, diastolic blood pressure (DBP) ≤ 40 mmHg or ≥ 90 mmHg or pulse rate (PR) ≥ 100 /min after at least 5 min sitting
  8. A subject with history of drug abuse or positive urine drug screening test
  9. A subject who has taken any prescribed medication or herbal compounds within 14 days prior to the study drug administration. In addition, a subject who has taken any over-the-counter drug or vitamin supplements within 7 days prior to the study drug administration (However, investigators can judge the subject, who has taken the medications during those periods above, eligible for the trial if all other conditions are satisfied.)
  10. A subject who has participated in any other clinical trial either for investigational or marketed drugs within 8 weeks before the study drug administration
  11. A subject who has donated or had loss of ≥ 400 mL of blood within 8 weeks prior to start of administration of study drug
  12. A subject who consumes more than 21 units of alcohol per week or unable to stop drinking throughout the study period.
  13. A smoker (except for whom quitted smoking prior to the drug administration for at least 3 months)
  14. A subject who heavily takes caffeine or caffeine-containing products, grapefruit, grapefruit juice, grapefruit-containing products
  15. A subject with unusual dietary habit
  16. A subject who was previously assigned to treatment during this study
  17. The investigator judges the subject not eligible for the study after reviewing clinical laboratory results or other reasons.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Screening
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: placebo
MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
Andre navne:
  • beta-lapachone
Eksperimentel: MB12066 10mg
MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
Andre navne:
  • beta-lapachone
Aktiv komparator: MB12066 30mg
MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
Andre navne:
  • beta-lapachone
Aktiv komparator: MB12066 100mg
MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
Andre navne:
  • beta-lapachone
Aktiv komparator: MB12066 150mg
MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
Andre navne:
  • beta-lapachone
Aktiv komparator: MB12066 200mg
MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
Andre navne:
  • beta-lapachone

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Safety/ Tolerability evaluation
Tidsramme: from day-1 to day8-10
Adverse events, Physical examinations, Vital signs, ECG (including continuous ECG monitoring), Laboratory tests (including hematology, chemistry, coagulation, PBS, NAD(P)+/NAD(P)H ratio, urinalysis), CIC
from day-1 to day8-10

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pharmacokinetic Evaluation
Tidsramme: between 0 (pre-dose) and 96 hours after a single oral dose.
  • Blood sampling time pre-dose, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h post-dose
  • Urine collection time 0h - 6h, 6h - 12h, 12h - 24h, 24h - 48h, 48h - 72h
  • Evaluation parameters AUClast, AUCinf, Cmax, Tmax, t1/2, Vd/F, CL/F, Ae, fe, CLR
between 0 (pre-dose) and 96 hours after a single oral dose.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Kyung-Sang Yu, Professor, Clinical Research Institute of Seoul National University Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. juli 2010

Primær færdiggørelse (Faktiske)

1. januar 2011

Studieafslutning (Faktiske)

1. januar 2011

Datoer for studieregistrering

Først indsendt

4. juli 2010

Først indsendt, der opfyldte QC-kriterier

26. januar 2011

Først opslået (Skøn)

28. januar 2011

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

27. juni 2018

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. juni 2018

Sidst verificeret

1. juni 2018

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med MB12066

Abonner